Clinical trials are a fundamental step in the development of Xencor’s monoclonal antibody therapeutics.

Clinical trials are research studies that are designed to determine if a medicine is safe and effective for patients. Patients may participate in ongoing clinical trials of Xencor’s investigational drug candidates if they meet certain enrollment criteria.

Ph 1 Study to Evaluate Safety and Tolerability of XmAb^®14045 in Patients With CD123-expressing Hematologic Malignancies

Condition: Acute Myelogenous Leukemia (AML); B-cell Acute Lymphoblastic Leukemia (B-ALL); Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Myeloid Leukemia (CML in blast phase)

Phase: Phase 1

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

View

Study to Evaluate Safety and Tolerability of XmAb^®13676 in Patients With CD20-expressing Hematologic Malignancies

Conditions: B-cell Non-Hodgkin’s Lymphoma; Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)

Phase: Phase 1

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

View

A Study of XmAb^®18087 in Subjects With NET and GIST

Conditions: Neuroendocrine Tumor (NET); Gastrointestinal Neoplasm (GIST)

Phase: Phase 1

This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first “priming” dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST.

View

A Study of XmAb^®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)

Conditions: Melanoma; Breast Carcinoma; Hepatocellular Carcinoma (HCC); Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Colorectal Carcinoma (CRC); Non-small Cell Lung Carcinoma (NSCLC); Gastric or Gastroesophageal Junction Adenocarcinoma; Endometrial Carcinoma

Phase: Phase 1

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

View

Information about Xencor’s clinical trials is available at www.clinicaltrials.gov.

Expanded Access Policy

CONTACT US

info@xencor.com
collaborate@xencor.com

Xencor, Inc. Headquarters
111 West Lemon Avenue
Monrovia, CA 91016
(626) 305-5900

Xencor, Inc. San Diego
12481 High Bluff Dr., Suite 200
San Diego, CA 92130
(858) 617-6155

Clinical trials are a fundamental step in the development of Xencor’s monoclonal antibody therapeutics.

Ph 1 Study to Evaluate Safety and Tolerability of XmAb®14045 in Patients With CD123-expressing Hematologic Malignancies

Study to Evaluate Safety and Tolerability of XmAb®13676 in Patients With CD20-expressing Hematologic Malignancies

A Study of XmAb®18087 in Subjects With NET and GIST

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)

CONTACT US

Ph 1 Study to Evaluate Safety and Tolerability of XmAb^®14045 in Patients With CD123-expressing Hematologic Malignancies

Study to Evaluate Safety and Tolerability of XmAb^®13676 in Patients With CD20-expressing Hematologic Malignancies

A Study of XmAb^®18087 in Subjects With NET and GIST

A Study of XmAb^®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)